Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial-Reference-Cited by-同舟云学术

Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial

Published:2023-05 Issue: Volume:91 Page:104586
ISSN:2352-3964
Container-title:eBioMedicine
language:en
Short-container-title:eBioMedicine

Author:

Gui Yu-Zhou,Li Xue-Ning,Li Jing-Xin,Shen Ming-Yun,Zhang Mei-Wei,Cao Ye,Xu Hong-Rong,Li Hui,Cheng Jie,Pan Liang,Yi Ying-Lei,Liang Li-Yu,Yu Cheng-Yin,Liu Gang-Yi,Yu Chen,Hu Bi-Jie,Zhu Feng-Cai,Liang Fei,Shen Haifa,Jia Jing-Ying^ORCID,Li Hang-Wen,Zhou Jian,Fan Jia

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference30 articles.

1. Evolutionary insight into the emergence of SARS-CoV-2 variants of concern;Nat Med,2022

2. Defining the risk of SARS-CoV-2 variants on immune protection;DeGrace;Nature,2022

3. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination;Cheng;Nat Med,2022

4. Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens;Klemis;Nat Commun,2022

5. BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19;Behrens;Nat Commun,2022

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Accelerating drug discovery, development, and clinical trials by artificial intelligence;Med;2024-09

2. mRNA therapies: Pioneering a new era in rare genetic disease treatment;Journal of Controlled Release;2024-05

3. Broad-spectrum Delta-BA.2 tandem-fused heterodimer mRNA vaccine delivered by lipopolyplex;PLOS Pathogens;2024-04-01

4. Global landscape of COVID-19 research: a visualization analysis of randomized clinical trials;Clinical and Experimental Medicine;2024-01-22

5. Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos);eClinicalMedicine;2024-01